Driving Simulator Performance After Administration of Analgesic Doses of Ketamine With Dexmedetomidine or Fentanyl
- 20 August 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 39 (5) , 446-454
Abstract
Purpose/Background: As a sole agent, ketamine acutely compromises driving ability; however, performance after coadministration with the adjuvant sedating agents dexmedetomidine or fentanyl is unclear. Methods/Procedures: Using a randomized within-subject design, 39 participants (mean ± SD age, 28.4 ± 5.8 years) received 0.3 mg/kg bolus followed by 0.15 mg kg−1 h−1 infusion of ketamine (3-hour duration), in addition to either (i) 0.7 μg kg−1 h−1 infusion of dexmedetomidine for 1.5 hours (n = 19; KET/DEX) or (ii) three 25 μg fentanyl injections for 1.5 hours (n = 20; KET/FENT). Whole blood drug concentrations were determined during ketamine only, at coadministration (KET/DEX or KET/FENT) and at 2 hours after treatment. Subjective effects were determined using a standardized visual analog scale. Driving performance was assessed at baseline and at posttreatment using a validated computerized driving simulator. Primary outcomes included SD of lateral position (SDLP) and steering variability (SV). Findings/Results: Administration of ketamine with dexmedetomidine but not fentanyl significantly increased SDLP (F 1,18 = 22.60, P < 0.001) and reduced SV (F1,18 = 164.42, P < 0.001) 2 hours after treatment. These deficits were comparatively greater for the KET/DEX group than for the KET/FENT group (t 37 = −5.21 [P < 0.001] and t 37 = 5.22 [P < 0.001], (respectively). For the KET/DEX group, vehicle control (SV) and self-rated performance (visual analog scale), but not SDLP, was inversely associated with ketamine and norketamine blood concentrations (in nanograms per milliliter). Greater subjective effects were moderately associated with driving deficits. Implications/Conclusions: Driving simulator performance is significantly compromised after coadministration of analgesic range doses of ketamine with dexmedetomidine but not fentanyl. An extended period of supervised driver abstinence is recommended after treatment, with completion of additional assessments to evaluate home readiness.Keywords
This publication has 30 references indexed in Scilit:
- A tutorial on sensitivity analyses in clinical trials: the what, why, when and howBMC Medical Research Methodology, 2013
- Dexmedetomidine and ketaminePediatric Critical Care Medicine, 2012
- Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP)International Journal of General Medicine, 2011
- Ketamine*Journal of Pain and Symptom Management, 2011
- Escort accompanying discharge after ambulatory surgery: a necessity or a luxury?Current Opinion in Anaesthesiology, 2009
- Psychoactive Medication and Traffic SafetyInternational Journal of Environmental Research and Public Health, 2009
- Ketamine and postoperative pain – a quantitative systematic review of randomised trialsPain, 2005
- Ketamine as Adjuvant Analgesic to Opioids: A Quantitative and Qualitative Systematic ReviewAnesthesia & Analgesia, 2004
- Clinical Policy for Procedural Sedation and Analgesia in the Emergency DepartmentAnnals of Emergency Medicine, 1998
- Driving Ability After Intravenous Fentanyl or DiazepamInvestigative Radiology, 1986